



Appointment of Company Secretary

24 May 2024: PharmAust Limited (ASX: PAA & PAAOA) (“PharmAust” or “the Company”) is pleased to announce the appointment of Mr Stefan Ross as Company Secretary, effective 24 May 2024.

Mr Ross has over 10 years’ experience in accounting and secretarial services for ASX listed companies. His extensive experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting and board and secretarial support.

Mr Ross will be the person responsible for communications with the ASX in relation to Listing Rule matters under Listing Rule 12.6.

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

For further information, please contact:

John Clark
Managing Director
investorenquiries@pharmaust.com

P: +61 (8) 9202 6814
F: +61 (8) 9467 6111
W: www.pharmaust.com

Media:
Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
0451 896 420

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process,” where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neuron disease (MND/ALS).

PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company recently announced positive top-line results for its Phase 1 study in patients with MND/ALS. PAA



anticipates commencing enrolment in its pivotal registration adaptive Phase 2/3 clinical study in H2 CY 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026.

The Neurodegenerative Disease Market size is estimated at USD 55.12 billion in 2024, and is expected to reach USD 77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).¹

¹<https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market>

PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting:

<https://investorhub.pharmaust.com/>

